Experimental Animal Facility, ICMR-National JALMA Institute For Leprosy & Other Mycobacterial Diseases, M. Miyazaki Marg, Tajganj, Agra, Uttar Pradesh, India.
KIIT-Technology Business Incubator (KIIT-TBI), Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar-751024.
Drug Discov Today. 2021 May;26(5):1245-1255. doi: 10.1016/j.drudis.2021.01.021. Epub 2021 Jan 23.
Increasing evidence suggests that mycobacteria change the host miRNA profile to their advantage. The active participation of miRNAs in controlling immune responses in TB has raised the possibility of utilizing miRNA-based therapy itself or canonically with a standard drug regimen for shortening the duration of treatment. The development of delivery systems for optimal delivery of oligonucleotides, including small interfering (si)RNA/miRNAs-based therapeutics has shown potential as a new therapeutic intervention. However, studies related to the exploitation of miRNAs as both biomarkers and as therapeutics in TB are scarce; thus, more in vitro and in vivo studies are required to fully determine the role of miRNAs as potential diagnostic biomarkers and to improve the pharmacological profile of this class of therapeutics.
越来越多的证据表明，分枝杆菌会改变宿主的 miRNA 谱，从而使其受益。miRNA 在控制结核病中的免疫反应方面的积极作用，使得 miRNA 为基础的治疗方法本身，或者与标准药物治疗方案联合使用，从而缩短治疗时间成为可能。开发用于最佳递送至包括小干扰 (si)RNA/miRNA 在内的寡核苷酸的递送系统已显示出作为一种新的治疗干预手段的潜力。然而，作为生物标志物和结核病治疗方法，miRNA 的开发相关研究仍然很少，因此需要更多的体外和体内研究来充分确定 miRNA 作为潜在的诊断生物标志物的作用，并改善该类治疗药物的药理学特性。
